Paediatric PK Study in Multiple Sclerosis Patients
Research payments
$1,760,913
Through program year 2025, $1,760,913 in research payments was reported against Paediatric PK Study in Multiple Sclerosis Patients, across 264 payments.
- Paid by (largest first)
- Genentech, Inc.; F. Hoffmann-La Roche AG; Roche Products Limited
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $260,238 | 43 |
| 2024 | Research | $305,005 | 43 |
| 2023 | Research | $265,776 | 53 |
| 2022 | Research | $272,608 | 60 |
| 2021 | Research | $335,325 | 39 |
| 2020 | Research | $318,951 | 25 |
| 2019 | Research | $3,010 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
5 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.